Control of in vivo collateral damage generated by T cell immunity

Journal of Immunology

Volumn 191, Issue 4, 2013, Pages 1686-1691

  Thangavelu, Govindarajan ^a   Gill, Ronald G ^b   Boon, Louis ^c   Ellestad, Kristofor K ^a   Anderson, Colin C ^a,d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF COLORADO   (United States)

^c BIOCEROS   (Netherlands)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; GAMMA INTERFERON; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CLONE; CELL DAMAGE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HOST; IMMUNOREGULATION; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; T LYMPHOCYTE; TISSUE INJURY; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD95; BYSTANDER EFFECT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; H-2 ANTIGENS; IMMUNITY, CELLULAR; IMMUNIZATION; INFLAMMATION; INTERFERON-GAMMA; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, IMMUNOLOGICAL; OVALBUMIN; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTE SUBSETS;

EID: 84881435479     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203240     Document Type: Article

References (29)

1. + cytotoxic T lymphocytes. Eur. J. Immunol. 28: 4162-4169.
2. + cytotoxic T lymphocytes. J. Virol. 72: 5948-5954.
3. + cytotoxic Tlymphocyte clones. J. Virol. 73: 3623-3629.
4. + cytotoxic T cell (CTL) clones: implications for CTL lytic mechanisms. Int. Immunol. 5: 1049-1058.
5. Sutton, R., D. W. Gray, P. McShane, M. J. Dallman, and P. J. Morris. 1989. The specificity of rejection and the absence of susceptibility of pancreatic islet β cells to nonspecific immune destruction in mixed strain islets grafted beneath the renal capsule in the rat. J. Exp. Med. 170: 751-762.
6. Korsgren, O., and L. Jansson. 1994. Characterization of mixed syngeneicallogeneic and syngeneic-xenogeneic islet-graft rejections in mice. Evidence of functional impairment of the remaining syngeneic islets in xenograft rejections. J. Clin. Invest. 93: 1113-1119.
7. Rosenberg, A. S., and A. Singer. 1988. Evidence that the effector mechanism of skin allograft rejection is antigen-specific. Proc. Natl. Acad. Sci. USA 85: 7739-7742.
8. Mintz, B., and W. K. Silvers. 1970. Histocompatibility antigens on melanoblasts and hair follicle cells. Cell-localized homograft rejection in allophenic skin grafts. Transplantation 9: 497-505.
9. McCullagh, P. 1985. Rejection of syngeneic skin grafts following retransplantation from histo-incompatible rats. Aust. J. Exp. Biol. Med. Sci. 63: 287-298.
10. Korsgren, O., A. C. Wallgren, M. Satake, and A. Karlsson-Parra. 1999. Xenograft rejection of fetal porcine islet-like cell clusters in the rat: effects of active and passive immunization. Xenotransplantation 6: 271-280.
11. + T cell survival but not for antigen proliferation. Nat. Immunol. 1: 54-58.
12. + T cells mediate graft rejection via a distinct effector pathway. Nat. Immunol. 3: 844-851.
13. Ehst, B. D., E. Ingulli, and M. K. Jenkins. 2003. Development of a novel transgenic mouse for the study of interactions between CD4 and CD8 T cells during graft rejection. Am. J. Transplant. 3: 1355-1362.
14. Nishimura, H., M. Nose, H. Hiai, N. Minato, and T. Honjo. 1999. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11: 141-151.
15. Chan, W. F. N., H. Razavy, and C. C. Anderson. 2008. Differential susceptibility of allogeneic targets to indirect CD4 immunity generates split tolerance. J. Immunol. 181: 4603-4612.
16. He, J. S., D. E. Gong, and H. L. Ostergaard. 2010. Stored Fas ligand, a mediator of rapid CTL-mediated killing, has a lower threshold for response than degranulation or newly synthesized Fas ligand. J. Immunol. 184: 555-563.
17. + T cells: perforin and FasL play alternate but obligatory roles. Am. J. Transplant. 7: 1927-1933.
18. + T lymphocytes. J. Clin. Invest. 105: 459-468.
19. Thangavelu, G., C. Smolarchuk, and C. C. Anderson. 2010. Co-inhibitory molecules: controlling the effectors or controlling the controllers? Self Nonself 1: 77-88.
20. Murphy, K. M., C. A. Nelson, and J. R. Sedý. 2006. Balancing co-stimulation and inhibition with BTLA and HVEM. Nat. Rev. Immunol. 6: 671-681.
21. -/- mice as an efficient animal model of type I diabetes. Proc. Natl. Acad. Sci. USA 102: 11823-11828.
22. + T helper 1 effectors. J. Immunol. 157: 2961-2968.
23. Handel, A., A. Yates, S. S. Pilyugin, and R. Antia. 2009. Sharing the burden: antigen transport and firebreaks in immune responses. J. R. Soc. Interface 6: 447-454.
24. Nyqvist, D., S. Speier, R. Rodriguez-Diaz, R. D. Molano, S. Lipovsek, M. Rupnik, A. Dicker, E. Ilegems, E. Zahr-Akrawi, J. Molina, et al. 2011. Donor islet endothelial cells in pancreatic islet revascularization. Diabetes 60: 2571-2577.
25. Krüger, B., N. Yin, N. Zhang, A. Yadav, W. Coward, G. Lal, W. Zang, P. S Heeger, J. S. Bromberg, B. Murphy, and B. Schröppel. 2010. Islet-expressed TLR2 and TLR4 sense injury and mediate early graft failure after transplantation. Eur. J. Immunol. 40: 2914-2924.
26. Anderson, C. C. 2009. On the sorting of the repertoire: an analysis of Cohn's challenge to integrity (Dembic), round 2. Scand. J. Immunol. 70: 321-325.
27. Yokosuka, T., M. Takamatsu, W. Kobayashi-Imanishi, A. Hashimoto-Tane, M. Azuma, and T. Saito. 2012. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J. Exp. Med. 209: 1201-1217.
28. Topalian, S. L., F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366: 2443-2454.
29. +high regulatory T cell function. J. Immunol. 169: 6210-6217.